Supplementary COVID 19 treatments


Head Honcho
Staff member
Two clinical trials suggest that specific antibody treatments can prevent deaths and hospitalizations among people with mild or moderate COVID-19 — particularly those who are at high risk of developing severe disease. . . .

The study results, both announced on 10 March, come from randomized, placebo-controlled, double-blind clinical trials, but have not yet been published. They add to a growing body of evidence that the treatments can help fend off severe disease when administered early, says Derek Angus, an intensive-care physician at the University of Pittsburgh in Pennsylvania.

The body’s natural response to viral infection is to generate a variety of antibodies, some of which are able to directly interfere with the virus’s ability to replicate. In the early days of the pandemic, researchers raced to identify the antibodies that are most effective against the coronavirus and to produce them in bulk. The resulting ‘monoclonal antibodies’ have since been tested in a variety of settings as treatments for COVID-19.

Vir and GSK’s antibody, called VIR-7831, was first isolated in 2003 from someone recovering from severe acute respiratory syndrome (SARS), which is caused by a similar coronavirus. The antibody was later found to bind to the SARS-CoV-2 ‘spike’ protein, too.

The antibodies “appear to be incredibly effective”, he says. “I’m very excited about the results of these trials.”

They are there, seem to work but hardly any clinic uses them. Hopefully the pubklication of the study will change that.PNG could sure whatever help there is!